TYRA
No price yet
Announcements
Nothing here yet
Daily updates
FDA designations
Nothing here yet
News
- Tyra Biosciences reported 79% ORR and 64% best overall complete response in Phase 2 SURF302 with dabogratinib for FGFR3-altered NMIBCSep 9, 2026
- Tyra Biosciences announces first child dosed in BEACH301 Phase 2 study for Dabogratinib (TYRA-300) in pediatric achondroplasiaAug 21, 2025
- Tyra Biosciences doses first patient in Phase 2 study of TYRA-300 for low-grade intermediate risk non-muscle invasive bladder cancerJun 30, 2025